Could an immune checkpoint drug slow Alzheimer's? early trial begins
NCT ID NCT05551741
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This first-in-human study tested a new drug called IBC-Ab002 in 40 people with early Alzheimer's disease. The drug is an antibody that targets PD-L1, a protein involved in immune regulation. The main goal was to check safety and how the drug moves through the body, not yet to prove it works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
IBC-Ab002 (an anti-PD-L1 antibody)
What this could lead to
If safe and effective, this could point toward a new way to treat Alzheimer's by targeting the immune system.
What could go wrong
This is a very early Phase 1 trial with only 40 participants, focused on safety. It is too small and early to know if the drug works, and it may fail in later studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER S DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Barzilai Medical Center
Ashkelon, Israel
-
Brain Research Center
Amsterdam, Netherlands
-
Dementia Research Centre, National Hospital for Neurology and Neurosurgery
London, United Kingdom
-
King's College London - Institute of Psychiatry, Psychology & Neuroscience (IoPPN)
London, SE5 8AF, United Kingdom
-
RICE - Research Institute for the Care of Older People
Bath, BA1 3NG, United Kingdom
-
Rabin Medical Center
Petah Tikva, Israel
-
Sheba Medical Center
Ramat Gan, Israel
-
Sheffield teaching Hospitals NHS Trust
London, United Kingdom
-
Tel-Aviv Sourasky Medical Center
Tel Aviv, Israel
-
University Hospital Southampton NHS Foundation Trust
Southampton, Hampshire, United Kingdom